Funding Support and Author Disclosures Dr Lavie has served as a speaker and consultant for AstraZeneca on their HF agent Farxiga. Dr Mehra has received travel support and consulting fees, paid to Brigham and Women’s Hospital, from Abbott; has received fees for serving on a steering committee from Janssen (Johnson & Johnson); has received fees for serving on a data and safety monitoring board from Mesoblast; has received consulting fees from Natera, Paragonix, Moderna, the Baim Institute of Clinical Research, and Broadview Ventures; and has received fees for serving as a scientific board member from NuPulseCV, Leviticus, Transmedics, and FineHeart. Dr Ventura has reported that he has no relationships relevant to the contents of this paper to disclose.